Volume 80, Issue 6 (September 2022)
Tehran Univ Med J 2022, 80(6): 470-476 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Haghighi R, Bavandi H, Kameli A, Razi A, Zeraati H. The effect of different doses of tamsulosin on lower urinary tract symptoms in patients with benign prostatic hyperplasia. Tehran Univ Med J 2022; 80 (6) :470-476
URL: http://tumj.tums.ac.ir/article-1-11872-en.html
URL: http://tumj.tums.ac.ir/article-1-11872-en.html
1- Deparment of Endourology and Urolaparoscopy, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
2- General Medicine Student, North Khorasan University of Medical Sciences, Bojnurd, Iran. ,Bavandih@gmail.com
3- Department of Anesthesiology, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
4- Deparment of Urology, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
2- General Medicine Student, North Khorasan University of Medical Sciences, Bojnurd, Iran. ,
3- Department of Anesthesiology, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
4- Deparment of Urology, Imam Hassan Hospital, North Khorasan University of Medical Sciences, Bojnurd, Iran.
Abstract: (900 Views)
Background: The prevalence of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) in men increases with age. Alpha-adrenergic receptor antagonists are first-line drugs for the treatment of LUTS, and tamsulosin is the drug of choice. The aim of this study was to compare the efficacy of tamsulosin 0.4 mg and 0.8 mg on lower urinary tract symptoms in patients with benign prostatic hyperplasia.
Methods: This double-blind clinical trial was conducted in the Urology unit of Emam Hassan Hospital in Bojnurd from May 2019 to Feb 2020. In this study, 92 patients with LUTS due to BPH were selected according to available method and randomly assigned into two groups of intervention. In the first group, patients received tamsulosin 0.4 mg and in the second group, tamsulosin 0.8 mg once daily for 8 weeks. The effectiveness of treatment was evaluated using IPSS criteria before and 8 weeks after treatment. According to a checklist, side effects were evaluated during treatment. Data was analyzed based on independent t-tests and repeated measures ANOVA by SPSS software version 22. A significance level of 0.05 was considered.
Methods: This double-blind clinical trial was conducted in the Urology unit of Emam Hassan Hospital in Bojnurd from May 2019 to Feb 2020. In this study, 92 patients with LUTS due to BPH were selected according to available method and randomly assigned into two groups of intervention. In the first group, patients received tamsulosin 0.4 mg and in the second group, tamsulosin 0.8 mg once daily for 8 weeks. The effectiveness of treatment was evaluated using IPSS criteria before and 8 weeks after treatment. According to a checklist, side effects were evaluated during treatment. Data was analyzed based on independent t-tests and repeated measures ANOVA by SPSS software version 22. A significance level of 0.05 was considered.
|
Results: The results showed that the two groups were not significantly different in age and duration of symptoms. According to the statistics test, there is a significant difference between the two groups in the post-treatment phase. Also, based on analysis of variance with repeated measures statistical test, there was a significant difference between and within two groups in IPSS criteria at different stages of evaluation. The prevalence of complications was (8.6%) in the first group and (11.9%) in the second group. The prevalence of complications was not significant between the two groups.
Conclusion: Tamsulosin is effective in reducing lower urinary tract symptoms and Tamsulosin 0.8 mg is an effective treatment regimen for the treatment of LUTS secondary to benign prostatic hyperplasia in those who have not responded to 0.4 mg treatment. Drug side effects were well tolerated in patients. |
Type of Study: Original Article |
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
